Search

Your search keyword '"Gimenez Arnau, Ana"' showing total 364 results

Search Constraints

Start Over You searched for: Author "Gimenez Arnau, Ana" Remove constraint Author: "Gimenez Arnau, Ana"
364 results on '"Gimenez Arnau, Ana"'

Search Results

3. Occupational Contact Urticaria Syndrome

6. Non–Skin Related Symptoms Are Common in Chronic Spontaneous Urticaria and Linked to Active and Uncontrolled Disease: Results From the Chronic Urticaria Registry

7. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials

8. Patient-Reported Outcome Measures in Atopic Dermatitis and Chronic Urticaria Are Underused in Clinical Practice

11. Drug Photosensitivity

12. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials

15. Patients With Chronic Spontaneous Urticaria Who Have Wheals, Angioedema, or Both, Differ Demographically, Clinically, and in Response to Treatment—Results From CURE

16. Urticaria exacerbations and adverse reactions in patients with chronic urticaria receiving COVID-19 vaccination: Results of the UCARE COVAC-CU study

17. Urticarial Vasculitis Differs From Chronic Spontaneous Urticaria in Time to Diagnosis, Clinical Presentation, and Need for Anti-Inflammatory Treatment: An International Prospective UCARE Study

18. The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria—CURE Results

19. Contact Dermatitis: Overcoming Challenges of Specific Patients, Deciphering the Results and Reaching a Correct Diagnosis

25. Safety of Remibrutinib Across Immune-mediated Diseases Supports Development in Multiple Sclerosis (P8-6.015)

26. Enhancing Angioedema Patient Care: Unveiling Underutilization and Barriers in the Implementation of Patient-Reported Outcome Measurements

28. Efficacy of Remibrutinib in Patients With Chronic Spontaneous Urticaria With or Without Prior Exposure to Biologics in the Phase 3 REMIX-1 and REMIX-2 Studies

30. Time to Relapse During Treatment-Free Follow-Up Without Remibrutinib in Patients With Chronic Spontaneous Urticaria: Subgroup Analysis By Baseline Immunoglobulin-E Levels and Chronic Urticaria Index Status From a Phase 2b Extension Study

35. How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE study

36. CRUSE®-An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria

39. Essentials and Updated Concepts

41. The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: A UCARE study

42. Emerging Systemic Treatment Options in Atopic Dermatitis.

44. CRUSE®—An innovative mobile application for patient monitoring and management in chronic spontaneous urticaria

45. Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials

47. Usage prevalence of angioedema patient–reported outcome measures: Results from the UCARE and ACARE PROMUSE study

50. Differential diagnosis between urticarial vasculitis and chronic spontaneous urticaria: An international Delphi survey

Catalog

Books, media, physical & digital resources